4.5 Article

Pharmacokinetics and Metabolism of 2-Aminothiazoles with Antiprion Activity in Mice

期刊

PHARMACEUTICAL RESEARCH
卷 30, 期 4, 页码 932-950

出版社

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-012-0912-4

关键词

antiprion drugs; drug discovery; IND24; IND81; prion disease

资金

  1. National Institutes of Health [AG002132, AG010770, AG031220, AG021601]

向作者/读者索取更多资源

To discover drugs lowering PrPSc in prion-infected cultured neuronal cells that achieve high concentrations in brain to test in mouse models of prion disease and then treat people with these fatal diseases. We tested 2-AMT analogs for EC50 and PK after a 40 mg/kg single dose and 40-210 mg/kg/day doses for 3 days. We calculated plasma and brain AUC, ratio of AUC/EC50 after dosing. We reasoned that compounds with high AUC/EC50 ratios should be good candidates going forward. We evaluated 27 2-AMTs in single-dose and 10 in 3-day PK studies, of which IND24 and IND81 were selected for testing in mouse models of prion disease. They had high concentrations in brain after oral dosing. Absolute bioavailability ranged from 27-40%. AUC/EC50 ratios after 3 days were > 100 (total) and 48-113 (unbound). Stability in liver microsomes ranged from 30-> 60 min. Ring hydroxylated metabolites were observed in microsomes. Neither was a substrate for the MDR1 transporter. IND24 and IND81 are active in vitro and show high AUC/EC50 ratios (total and unbound) in plasma and brain. These will be evaluated in mouse models of prion disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据